Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.62 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.62 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.62 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28207776 | 0.98 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL21367529 | 0.98 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL28243190 | 0.98 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL3959388 | 0.95 | GNAI3 (0.62) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL24437800 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL561543 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL1485554 | 0.93 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL3326405 | 0.93 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL7778149 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL9801263 | 0.93 | GNAI3 (0.66) | GNAI3GNAO1GNAI1S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602955-B | Photocuring method, compound used in photocuring method, and composition | 富士胶片和光纯药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-107848963-B | Acid-resistant alkali-producing agent and/or radical-producing agent, and curable resin composition containing same | 富士胶片和光纯药株式会社 | 2020-11-03 | — | — | CN | disclosed |
| US-10775388-B2 | Methods of using antibodies to determine periostin levels in a sample | MEDIMMUNE, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| CN-110678500-A | Photo-or thermosetting method and curable resin composition | 富士胶片和光纯药株式会社 | 2020-01-10 | — | — | CN | disclosed |
| CN-108602955-A | The compound and composition used in process for photocuring, the process for photocuring | 富士胶片和光纯药株式会社 | 2018-09-28 | — | — | CN | disclosed |
| US-20180196065-A1 | NOVEL ASSAY TO DETECT HUMAN PERIOSTIN | MEDIMMUNE, LLC | 2018-07-12 | — | — | US | disclosed |
| CN-107848963-A | Alkali-producing agent and/or radical-generating agent having acid resistance, and curable resin composition containing same | 和光纯药工业株式会社 | 2018-03-27 | — | — | CN | disclosed |
| US-20110098300-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | US | disclosed |
| EP-2300426-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2011-03-30 | — | — | EP | disclosed |
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | disclosed |
| EP-2146980-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma S.A. (BE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009147149-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008128919-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA S.A. (BE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | HMGCR, TECR, CYP4A11 | GNAI3 3373/4885GNAO1 2653/4885GNAI1 3645/4885 |
| US-20110098300-A1 | Compounds Comprising A Cyclobutoxy Group | CHAT, BACE1, GRIN2B | GNAI3 1546/4885GNAO1 441/4885GNAI1 1461/4885 |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | CYP11B2, CYP11B1, CYP4B1 | GNAI3 1792/4885GNAO1 1280/4885GNAI1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.